Respiratorius (RESP) | Spotlight

Respiratorius is a research company. Today, the company is mainly focused on development of new drug candidates for the treatment of chronic obstructive pulmonary disease (COPD), asthma and cancer. Additionally, the company focuses on project development in the area of cardiovascular diseases. The company was formed in 1999 as a spin-off from Lund University. The company is based in Lund.

Quotes for Respiratorius AB

Right Now

+/-: 0.04
%: 2,94%
Latest: 1.4
High: 1.4
Low: 1.3
Volume: 236 062
Turnover (SEK): 316 680
Value (MSEK): 220,0

Board

CEO

Johan Drott

Chairman Of The Board

Christer Fåhræus

Board

Anna Törner
Ingemar Kihlström
Kristina Drott
Olov Sterner
Sarah Fredriksson

News

2019-11-18 08:56:25 Respiratorius - Valberedning utsedd
2019-11-07 08:24:45 KVARTALSRAPPORT 3, 2019
2019-11-06 09:11:38 Canada grants patent for VAL001
2019-11-05 20:15:00 Kanadas patentverk beviljar patent för VAL001
2019-08-30 11:37:13 Halvårsrapport 2019

Show More

News agencies

2019-11-19 15:15:04 Finwire: Respiratorius fortsätter jakten på partner till VAL001
2019-11-18 10:00:47 Finwire: Respiratorius har utsett sin valberedning
2019-11-07 08:34:12 Finwire: Respiratorius redovisar som planerat små förändringar av resultatet
2019-11-06 07:13:29 Finwire: Respiratorius får patentgodkännande i Kanada
2019-08-30 15:14:15 Finwire: Respiratorius redovisar som förväntat inga intäkter i andra kvartalet

Show More

Analysis

2019-03-19 SvD Börsplus: Emission eller exit?
2018-01-09 SvD Börsplus: Andlös spänning för Respiratorius inför årets ödesbesked
2014-11-18 Redeye: Väntans tider är goda tider
2014-07-21 Redeye: Lättare luft att andas

Videos

Upcoming reports

2020-02-04 Bokslutskommuniké 2019

Annual reports, prospectus etc.